by tmourit | Nov 14, 2025 | Audits, Quality, Regulatory
In the life sciences industry, patient safety is non-negotiable. Whether you’re developing pharmaceuticals, biologics, or medical devices, establishing a robust pharmacovigilance (PV) and safety reporting system is critical to compliance, product integrity, and public... by tmourit | Nov 7, 2025 | Audits, Quality, Regulatory
In the life sciences industry, your products are only as reliable as the partners you depend on. Whether you’re sourcing raw materials, reagents, packaging components, or contract manufacturing and testing services, supplier qualification and ongoing monitoring are... by tmourit | Oct 31, 2025 | Audits, Quality, Regulatory
Medical device and diagnostic manufacturers face increasingly complex regulatory landscapes — especially when bringing products to both the United States and the European Union. While the U.S. FDA and the EU MDR/IVDR frameworks share the same ultimate goal, ensuring... by tmourit | Oct 23, 2025 | Audits, Quality, Regulatory
What Is Risk-Based Quality Management (RBQM), and How Is It Applied? Risk-Based Quality Management (RBQM) has become one of the most transformative approaches in modern clinical research and quality systems. Rather than treating every process or data point equally,... by tmourit | Oct 10, 2025 | Audits, Quality, Regulatory
Clinical trials are the backbone of medical innovation. They provide the evidence regulators need to determine whether a drug, biologic, or device is safe and effective for patients. But designing and monitoring a clinical trial is not just a scientific process — it’s... by tmourit | Oct 5, 2025 | Audits, Quality, Regulatory
What Is an FDA 483? An FDA Form 483 is issued at the conclusion of an inspection when an investigator observes conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or related regulations. It is not an official enforcement action—but it is a formal...